ArticleThe Journal of dermatology2026

Real-World Outcomes of Baricitinib and Ritlecitinib in Refractory Alopecia Areata: Response Predictors and Relapse After Discontinuation or Dose Reduction.

Rina Hayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.